NCT02601209: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 23 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02601209 |
|---|---|
| Title | A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 30, 2015 |
| Completion date | Dec. 7, 2018 |
| Required reporting date | Dec. 7, 2019, midnight |
| Actual reporting date | Dec. 30, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 23 |